An update of new targets for cancer treatment: Receptor-mediated signals

Annals of Oncology

Volumn 13, Issue SUPPL. 4, 2002, Pages 29-38

  Ciardiello, F ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AMINOTRANSFERASE; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; HR 3; IMC 225; IRINOTECAN; LAPATINIB; MATUZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY Y 10; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PROTEIN TYROSINE KINASE; RALTITREXED; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; ASTHENIA; AUTOCRINE EFFECT; AUTOPHOSPHORYLATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CELL FUNCTION; CELL PROLIFERATION; CHILL; DIARRHEA; DRUG DESIGN; DRUG HYPERSENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; FEVER; HUMAN; LIGAND BINDING; METASTASIS; MOUSE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; RASH; SIGNAL TRANSDUCTION; SKIN TOXICITY; THROMBOCYTOPENIA;

EID: 0036433244     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf635     Document Type: Article

References (95)

1. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Haematol 1995; 19: 183-232.
2. Salomon DS, Gullick W. The erbB family of receptors and their ligands: multiple targets for therapy. Signal 2001; 2: 4-11.
3. Pedersen MW, Meltorn M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation. Ann Oncol 2001; 12: 745-760.
4. McClelland RA, Barrow D, Madden T-A et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001; 142: 2776-2788.
5. Akimoto T, Hunter NR, Buchmiller L et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine, carcinomas. Clin Cancer Res 1999; 5: 2884-2890.
6. Wosikowski K, Schuuruis D, Kops GJPL et al. Altered gene expression in drug-resistant human breast cancer cells. Clin Cancer Res 1997; 3: 2405-2414.
7. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Rel Cancer 2001; 8: 3-9.
8. Sporn MB, Todaro GJ. Autocrine secretion and malignant transformation of cells. N Engl J Med 1980; 303: 878-880.
9. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19: 6550-6565.
10. Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy. Clin Cancer Res 2000; 6: 747-753.
11. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1992; 53: 4637-4642.
12. Baselga J, Norton L, Masui H et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85: 1327-1333.
13. Goldstein NI, Prewett M, Zuklys K et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1: 1311-1318.
14. Prewett M, Rockwell P, Rockwell RF et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Tumor Immunol 1996; 19: 419-427.
15. Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994; 269: 27595-27602.
16. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996; 12: 1397-1403.
17. 1 arrest in prostatic cancer cell line DU145. Cancer Res 1996; 56: 3666-3669.
18. Ciardiello F, Damiano V, Bianco R et al. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst 1996; 88: 1770-1776.
19. Ciardiello F, Bianco R, Damiano V et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999; 5: 909-916.
20. Prewett M, Rothman M, Waksal H et al. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 1998; 4: 2957-2966.
21. Perrotte P, Matsumoto T, Inoue K et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5: 257-265.
22. Bruns CJ, Harbison MT, Davis DW et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000; 6: 1936-1948.
23. Ciardiello F, Bianco R, Damiano V et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res. 2000; 6: 3739-3747.
24. Inoue K, Slaton JW, Perrotte P et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000; 6: 4874-4884.
25. Saleh MH, Raisch KP, Stackhouse MA et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 1999; 14: 451-463.
26. Milas L, Mason K, Hunter N et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6: 701-708.
27. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radio-sensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 15: 1935-1940.
28. Bianco C, Bianco R, Tortora G et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 2000; 6: 4343-4350.
29. Huang S-M, Harari P. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000; 6: 2166-2174.
30. Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18: 904-914.
31. Albanell J, Codony-Servant J, Rojo F et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor a expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatment. Cancer Res 2001; 61: 6500-6510.
32. Shin DM, Donato NJ, Perez-Soler R et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001; 7: 1204-1213.
33. Rubin MS, Shin DM, Pasmantier M et al. Monoclonal antibody (MoAb) IMC-225, an anti-epidermal growth factor receptor (EGFr), for patients (Pts) with EGFr-positive tumors refractory to or in relapse from previous therapeutic regimens. Proc Am Soc Clin Oncol 2000; 19: (Abstr 1860).
34. Gunnett K, Motzer R, Amato R et al. Phase II study of anti-epidermal growth factor receptor (EGFr) antibody C225 alone in patients (pts) with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 1999; 18: (Abstr 1309).
35. Robert F, Ezekiel MP, Spencer SA et al. Phase I study of anti-epidermal growth factor receptor antibody Cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19: 3234-3243.
36. Abbruzzese JL, Rosenberg A, Xiong Q et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2001; 20: (Abstr 518).
37. Saltz L, Rubin M, Hochster H et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20: (Abstr 7).
38. Saltz L, Rubin M, Hochster H et al. Acne-like rash predicts response in patients treated with Cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2001; (Abstr 559).
39. Hong WK, Arquette M, Nabell L et al. Efficacy and safety of the anti-epidermal growth factor receptor antibody (EGFR) IMC-C225 in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 2001; 20: (Abstr 895).
40. Yang X-D, Jia X-C, Corvolan JRF et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17-23.
41. Viloria-Petit A, Crombet T, Jothy S et al. Acquired resistance to the antitumor activity of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61: 5090-5101.
42. Hambek M, Solbach C, Schnuerch H-G et al. Tumor necrosis factor a sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Cancer Res 2001; 61: 1045-1049.
43. Sampson JH, Crotty LE, Lee S et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci USA 2000; 97: 7503-7508.
44. Mishima K, Johns TG, Luwor RB et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 2001; 61: 5349-5354.
45. Luwor RB, Johns TG, Murone C et al. Monoclonal antibody 806 the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 2001; 61: 5355-5361.
46. Figlin R, Belldegrun A, Crawford J et al. Clinical results: a fully human anti-EGFr antibody in patients with advanced cancer. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2001; (Abstr 654).
47. Ciardiello F, Caputo R, Bianco R et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-2063.
48. Chan KC, Knox F, Woodburn JR et al. Blockade of growth factor receptors in ductal carcinoma in situ of the breast inhibits epithelial proliferation. Br J Surg 2001; 88: 412-418.
49. Cullinane C, Kleinschmidt M, Webster LK. Antitumor activity of ZD1839 ('Iressa') in combination with cisplatin in NIH3T3 cells expressing human epidermal growth factor receptor. Proc Am Assoc Cancer Res 2000; 41: A3073.
50. Sirotnak FM, Zakowsky MF, Miller VA et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 4885-4892.
51. 1 arrest and enhancing the antitumor effect of interferon α. Proc Am Assoc Cancer Res 2000; 41: A4910.
52. Ohmori T, Ao Y, Nishio K et al. Low dose cisplatin can modulate the sensitivity of human non-small cell lung carcinoma cells to EGFR tyrosine kinase inhibitor (ZD1839; 'Iressa') in vivo. Proc Am Assoc Cancer Res 2000; 41: A3072.
53. Lichtner RB, Menrad A, Sommer A et al. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 2001; 61: 5790-5795.
54. Ciardiello F, Caputo R, Bianco R et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001; 7: 1459-1465.
55. Ciardiello F, Caputo R, Bianco R et al. ZD1839 ('Iressa'), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 2002; 98: 463-469.
56. Raben D, Helfrich B, Phistry M, Bunn P. ZD1839 (Iressa), an EGFR-TKI, potentiates radiation/chemotherapy cytotoxicity in human non-small cell lung cancer (NSCLC) cell lines. Eleventh NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy 2000; (Abstr LB4).
57. Williams K, Telfer BA, Stratford IJ, Wedge SR. An evaluation of the EGFR tyrosine kinase inhibitor ZD1839 (Iressa) in combination with ionising radiation. Eleventh NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy 2000; (Abstr LB3).
58. Normanno N, Campiglio M, De Luca A et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2001; 13: 65-72.
59. Moulder SL, Yakes FM, Muthuswamy SK et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001; 61: 8887-8895.
60. Anido J, Albanell J, Rojo F et al. Inhibition by ZD1839 (Iressa) of epidermal growth factor (EGF) and heregulin induced signaling pathways in human breast cancer cells. Proc Am Soc Clin Oncol 2001; 20: (Abstr 1712).
61. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001; 61: 7184-7188.
62. Kris MG, Herbst R, Rischin D et al. Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD1839 ('Iressa'), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer 2000; 29 (Suppl. 1): A233.
63. Tamura T, Nakagawa K, Fukuoka M et al. A phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with solid malignant tumors. Lung Cancer 2000; 29 (Suppl. 1): A229.
64. Ferry D, Hammond L, Ranson M et al. Intermittent oral ZD1839 ('Iressa'), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: final results from a phase I study. Proc Am Soc Clin Oncol 2000; 19: (Abstr 5E).
65. Baselga J, Herbst R, Lorusso P et al. Continuous administration of ZD1839 ('Iressa'), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability. Proc Am Soc Clin Oncol 2000; 19: (Abstr 686).
66. Goss G, Hirte H, Lorimer I et al. Final results of the dose-escalation phase of a phase I, dose-escalation, pharmacokinetics (PK) and pharmacodynamic study of ZD1839: NCIC CTG IND. 122. Proc Am Soc Clin Oncol 2001; 20: (Abstr 2368).
67. Albanell J, Rojo F, Averbuch S et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20: 110-124.
68. Baselga J, Yano S, Gaiccone G et al. Initial results from a phase II trial of ZD1839 (Iressa) as second- and third-line monotherapy for patients with advanced non-small-cell lung cancer (IDEAL 1). AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2001; (Abstr 630A).
69. Laurie SA, Miller VA, Johnson D et al. Pilot trial of ZD1839 ('Iressa'), an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, in combination with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer (NSCLC). Lung Cancer 2000; 29 (Suppl. 1): A230.
70. Miller VA, Johnson D, Heelan RT et al. A pilot trial demonstrates the safety of ZD1839 (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small lung cancer (NSLC). Proc Am Soc Clin Oncol 2001; 20: A1301.
71. Giaccone G, Gonzales-Larriba JL, Smit EF et al. Combination therapy with ZD1839 (Iressa), an orally active, selective, epidermal growth factor receptor tyrosine inhibitor (EGFR-TKI), gemcitabine and cisplatin, in patients with advanced solid tumors: promising preliminary results on tolerability, efficacy, and pharmacokinetics. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2001; (Abstr 553).
72. Hammond LA, Figueroa J, Schwartzberg L et al. Feasibility and pharmacokinetic (PK) trial of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with 5-fluorouracil (5-FU) and leucovorin in patients with advanced colorectal cancer (aCRC). Proc Am Soc Clin Oncol 2001; 20:544.
73. Moyer JD, Barbacci EG, Iwata KK et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57: 4838-4848.
74. Pollack VA, Savage DM, Baker DA et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291: 739-748.
75. Karp DD, Ferrante KJ, Tensfeldt TG et al. A phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumors. Lung Cancer 2000; 29 (Suppl 1.): A208.
76. Siu LL, Hidalgo M, Nemunaitis J et al. Dose and schedule-duration escalation of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358, 774: a Phase I and pharmacokinetic (PK) study. Proc Am Soc Clin Oncol 1999; 18: 1498.
77. Karp DD, Silberman SL, Csudae R et al. Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 1999; 18: 1499.
78. Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 13: 3267-3279.
79. Senzer NN, Soulieres D, Siu L et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 2001; 20: 6.
80. Finkler N, Gordon A, Crozier M et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc Am Soc Clin Oncol 2001; 20: 831.
81. Perez-Soler R, Chachoua A, Huberman M et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20: 1235.
82. Fry DW, Bridges AJ, Denny WA et al. Specific, irreversible inactivation of the epidermal growth factor receptor, and erbB2, by a new class of tyrosine kinase inhibitors. Proc Natl Acad Sci USA 1998; 95: 12022-12027.
83. Rao GS, Murray S, Ethier SP. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Rad Oncol Biol Phys 2000; 48: 1519-1528.
84. Shin DM, Nemunaitis J, Zinner RG et al. A phase I clinical and biomarker study of CI-1033, a novel pan-erbB tyrosine kinase inhibitor in patients with solid tumors. Proc Am Soc Clin Oncol 2001; 20: 324.
85. Garrison MA, Tolcher A, McCreery H et al. A phase I and pharmacokinetic study of CI-1033, a pan-erbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors. Proc Am Soc Clin Oncol 2001; 20: 283.
86. Traxler P, Buchdunger E, Furet P et al. Preclinical profile of PKI-166, a novel and potent EGFR tyrosine kinase inhibitor for clinical development. Clin Cancer Res 1999; 5: A100.
87. Bruns CJ, Solorzano CC, Harbison MT et al. Blockade of the epidermal growth factor receptor signalling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000; 60: 2926-2935.
88. Zinner RG, Nemunatis JJ, Donato NJ et al. A phase I clinical and biomarker study of the novel pan-erbB tyrosine kinase inhibitor, CI-1033, in patients with solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2001; (Abstr 566).
89. Rusnak DW, Affleck K, Cockerill SG et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001; 61: 7196-7203.
90. Rusnak DW, Lackey K, Affleck K et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85-94.
91. Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 1997; 89: 341-343.
92. Ryan PD, Chabner BA. On receptor inhibitors and chemotherapy. Clin Cancer Res 2000; 6: 4607-4609.
93. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958-2970.
94. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002; 62: 200-207.
95. Ciardiello F, Caputo R, Bianco R et al. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. J Natl Cancer Inst 1998; 90: 1087-1094.